131 related articles for article (PubMed ID: 38350654)
1. Impacts of hyperthermic chemotherapeutic agent on cytotoxicity, chemoresistance-related proteins and PD-L1 expression in human gastric cancer cells.
Su BC; Chen GY; Yang CM; Chuang WT; Lin MC; Hsu PL; Lee CW; Cheng CC; Wu SY; Pan BS; Yu HH
Int J Hyperthermia; 2024; 41(1):2310017. PubMed ID: 38350654
[No Abstract] [Full Text] [Related]
2. The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines.
Helderman RFCPA; Löke DR; Verhoeff J; Rodermond HM; van Bochove GGW; Boon M; van Kesteren S; Garcia Vallejo JJ; Kok HP; Tanis PJ; Franken NAP; Crezee J; Oei AL
Cells; 2020 Jul; 9(8):. PubMed ID: 32722384
[TBL] [Abstract][Full Text] [Related]
3. Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil.
Seo JH; Jeong ES; Lee KS; Heo SH; Jeong DG; Choi YK
Int J Oncol; 2013 Dec; 43(6):2007-14. PubMed ID: 24100731
[TBL] [Abstract][Full Text] [Related]
4. 5-fluorouracil combined with cisplatin and mitomycin C as an optimized regimen for hyperthermic intraperitoneal chemotherapy in gastric cancer.
Murata S; Yamamoto H; Shimizu T; Naitoh H; Yamaguchi T; Kaida S; Takebayashi K; Miyake T; Tani T; Tani M
J Surg Oncol; 2018 Mar; 117(4):671-677. PubMed ID: 29266509
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and safety of hyperthermic intraperitoneal chemotherapy using 5-fluorouracil combined with cisplatin and mitomycin C in patients undergoing gastrectomy for advanced gastric cancer.
Murata S; Yamamoto H; Naitoh H; Yamaguchi T; Kaida S; Shimizu T; Shiomi H; Naka S; Tani T; Tani M
J Surg Oncol; 2017 Dec; 116(8):1159-1165. PubMed ID: 28743181
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Selective Immune-Active Mild Hyperthermia Associated with Chemotherapy in Colon Peritoneal Metastasis by Photoactivation of Fluorouracil-Gold Nanoparticle Complexes.
Mulens-Arias V; Nicolás-Boluda A; Pinto A; Balfourier A; Carn F; Silva AKA; Pocard M; Gazeau F
ACS Nano; 2021 Feb; 15(2):3330-3348. PubMed ID: 33528985
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CCCTC Binding Factor-Programmed Cell Death Ligand 1 Axis Suppresses Emergence of Chemoresistance Induced by Gastric Cancer-Derived Mesenchymal Stem Cells.
Wang Q; Huang C; Ding Y; Wen S; Wang X; Guo S; Gao Q; Chen Z; Zhao Y; Wang M; Shen B; Zhu W
Front Immunol; 2022; 13():884373. PubMed ID: 35572560
[TBL] [Abstract][Full Text] [Related]
8. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
[TBL] [Abstract][Full Text] [Related]
9. Gene expression changes induced by HIPEC in a murine model of gastric cancer.
Graziosi L; Mencarelli A; Renga B; Santorelli C; Cantarella F; Bugiantella W; Cavazzoni E; Donini A; Fiorucci S
In Vivo; 2012; 26(1):39-45. PubMed ID: 22210714
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic intraperitoneal chemotherapy using a combination of mitomycin C,5-fluorouracil, and oxaliplatin in patients at high risk of colorectal peritoneal metastasis: A Phase I clinical study.
Shimizu T; Sonoda H; Murata S; Takebayashi K; Ohta H; Miyake T; Mekata E; Shiomi H; Naka S; Tani T
Eur J Surg Oncol; 2014 May; 40(5):521-528. PubMed ID: 24388411
[TBL] [Abstract][Full Text] [Related]
11. Blockage of PD-L1 by FERMT3-mediated Wnt/β-catenin signalling regulates chemoresistance and immune evasion of colorectal cancer cells.
Tang Y; Nan N; Gui C; Zhou X; Jiang W; Zhou X
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):988-997. PubMed ID: 35672907
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and Predictive Value of Microsatellite Instability, Inflammatory Reaction and PD-L1 in Gastric Cancer Patients Treated with Either Adjuvant 5-FU/LV or Sequential FOLFIRI Followed by Cisplatin and Docetaxel: A Translational Analysis from the ITACA-S Trial.
Di Bartolomeo M; Morano F; Raimondi A; Miceli R; Corallo S; Tamborini E; Perrone F; Antista M; Niger M; Pellegrinelli A; Randon G; Pagani F; Martinetti A; Fucà G; Pietrantonio F;
Oncologist; 2020 Mar; 25(3):e460-e468. PubMed ID: 32162808
[TBL] [Abstract][Full Text] [Related]
13. Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro.
Shchepotin IB; Shabahang M; Nauta RJ; Buras RR; Brenner RV; Evans SR
Surg Oncol; 1994 Oct; 3(5):287-94. PubMed ID: 7889222
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
[TBL] [Abstract][Full Text] [Related]
15. Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1/PD- L1-dependent T cell immunization.
Xu R; Wu J; Zhang X; Zou X; Li C; Wang H; Yuan M; Chen M; Sun Q; Liu S
Pharmacol Res; 2020 Feb; 152():104623. PubMed ID: 31899315
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial.
Yang XJ; Huang CQ; Suo T; Mei LJ; Yang GL; Cheng FL; Zhou YF; Xiong B; Yonemura Y; Li Y
Ann Surg Oncol; 2011 Jun; 18(6):1575-81. PubMed ID: 21431408
[TBL] [Abstract][Full Text] [Related]
17. Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results.
van der Kaaij RT; Wassenaar ECE; Koemans WJ; Sikorska K; Grootscholten C; Los M; Huitema A; Schellens JHM; Veenhof AAFA; Hartemink KJ; Aalbers AGJ; van Ramshorst B; Boerma D; Boot H; van Sandick JW
Br J Surg; 2020 Oct; 107(11):1520-1528. PubMed ID: 32277764
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic Intraperitoneal Chemotherapy in the Management of Gastric Cancer: A Narrative Review.
Mazurek M; Szlendak M; Forma A; Baj J; Maciejewski R; Roviello G; Marano L; Roviello F; Polom K; Sitarz R
Int J Environ Res Public Health; 2022 Jan; 19(2):. PubMed ID: 35055500
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of hyperthermic intraperitoneal chemotherapy in gastric cancer with synchronous peritoneal metastases: a real-world retrospective study.
Guo J; Deng Z; Jin L; Yin S; Xiong Z; Wang C; Chen H; Luo D; Huang D; Peng J; Chen S; Lian L
J Cancer Res Clin Oncol; 2023 Dec; 149(20):17881-17896. PubMed ID: 37947869
[TBL] [Abstract][Full Text] [Related]
20. Extract of
Cui XL; Li KJ; Ren HX; Zhang YJ; Liu XD; Bu BG; Wang L
World J Gastroenterol; 2019 Apr; 25(15):1854-1864. PubMed ID: 31057299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
